Cannabis Use in Cancer Patients
Effects of Cannabis Use in Cancer Patients: A Feasibility Study
Study Overview
Status
Status
Conditions
Conditions
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Contacts and Locations
Study Contact
Study Contact
- Name: Angela Bryan, PhD
- Phone Number: 303-492-8264
- Email: angela.bryan@colorado.edu
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University Of Colorado Hospital
-
Boulder, Colorado, United States, 80309
- University of Colorado Boulder
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
In order to be eligible to participate in this study, an individual must meet all of the following criteria:
- Provision to sign and date the consent form.
- Stated willingness to comply with all study procedures and be available for the duration of the study.
- Be a female or male aged at least 21 years.
- Have a diagnosis of any solid tumor type who has or is undergoing either curative or palliative treatment
- Have intent or interest to use cannabis to treat their symptoms.
Exclusion Criteria:
An individual who meets any of the following criteria will be excluded from participation in this study:
- Report of other non-prescription drug use, such as cocaine, heroin, methamphetamine in the past 60 days
- Actively seeking or in treatment for any substance use disorder
- Acute illness other than cancer that could affect cognition or compliance per the decision of the study M.D.
- Premenopausal females who are pregnant or trying to become pregnant. Note that pregnancy testing will not be required.
- A Telephone Interview for Cognitive Status (TICS) score indicating moderate or severe cognitive impairment at screening
Study Plan
How is the study designed?
Design Details
Number of groups / cohorts
Cohorts and Interventions
Group / CohortGroup / Cohort |
|---|
|
Oral Cannabis
This is an observational study of individuals who have already decided to try cannabis for their cancer treatment-related symptoms.
A research assistant will provide information on the range of edible cannabis products and basic information about their various cannabinoid profiles, approximate prices, and nearby locations where participants may choose to purchase their product.
Participants will then initiate use of an orally administered product they have selected and obtained.
Participants will take the product as they see fit, without any frequency or dosing instructions from study staff, for two weeks.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Likelihood of Accruing Participants: Feasibility of Enrollment
Time Frame: Approximately 48 months
|
Enroll a minimum of 30 patients and demonstrate reasonable compliance with study procedures within 54 months of active recruiting.
|
Approximately 48 months
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Amount of Interest
Time Frame: Approximately 48 months
|
Study officials will document how many patients contact the research team regarding their participation in the study
|
Approximately 48 months
|
|
Eligibility
Time Frame: Approximately 48 months
|
Study officials will document how many patients are and are not eligible to participate in the study.
|
Approximately 48 months
|
|
Enrollment
Time Frame: Approximately 48 months
|
Study officials will document how many patients actually proceed to enrollment in the study.
|
Approximately 48 months
|
|
Completion of Assessments
Time Frame: Baseline to one month follow up, Approximately 48 months
|
Study officials will document how many participants complete each assessment (baseline assessment, pre-acute cannabis use assessment, 1 hour post-acute cannabis use, 2 hour post-acute cannabis use, one month follow up assessment).
|
Baseline to one month follow up, Approximately 48 months
|
|
Study Completion
Time Frame: Approximately 48 months
|
Study officials will document how many participants complete the study in its entirety.
|
Approximately 48 months
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Angela Bryan, PhD, University of Colorado, Denver
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 18-0836.cc
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.